Extended Data Figure 1: Metabolomics characterization of mouse and human prostate cancer.
From: mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer
a, Incidence of pathological alterations observed in Ptenpc+/+ and Ptenpc−/− mice. Number of mice as indicated. LG-PIN, low-grade prostatic intraepithelial neoplasia; HG-PIN: high-grade prostatic intraepithelial neoplasia; Focal Adc, focal adenocarcinoma. b, Representative immunohistochemical images of prostate tissue stained with haematoxylin and eosin (H&E), Pten, AktS473, and RpS6S235/6 from mice at 3 and 6 months of age (representative of three mice per condition). c, Experimental design of the TOF-MS metabolomics analysis. AP, anterior prostate; DLP, dorsolateral prostate. d, e, Volcano plot (d) and principal component analysis (PCA, e) from altered metabolites in TOF-MS metabolomic analysis performed in Ptenpc−/− and Ptenpc+/+ mouse prostate samples at the indicated age (6 months Ptenpc+/+anterior prostate, n = 4 mice; remainder of conditions, n = 5 mice). Grey dots: not significantly altered; red dots: significantly increased in Ptenpc−/− prostate extracts; blue dots: significantly decreased in Ptenpc−/− prostate extracts. f, LC/MS analysis of methionine cycle and polyamine pathway metabolites from Ptenpc−/− versus Ptenpc+/+ mouse prostate samples at the indicated age (anterior prostate 3 months, n = 5 mice; 6 months, n = 4 mice). Median ± interquartile range. g, LC/MS analysis of methionine cycle and polyamine pathway metabolites from prostate cancer versus BPH human specimens (six prostate specimens per condition). Median ± interquartile range. *P < 0.05; **P < 0.01; ***P < 0.001. One-tailed Mann–Whitney U-test (f, g) was used for data analysis.
